Category Archives: Clinical Accelerator

First Verified Data Release from VAL401 Phase II Clinical Trial

Below, we are re-publishing with permission the press-release issued by ValiSeek on the 28th of September 2017  ValiRx Plc (“ValiRx” or the “Company”) VALISEEK CLINICAL DEVELOPMENT UPDATE “First Verified Data Release from VAL401 Phase II Clinical Trial” London, UK., 28 September … Continue reading

Posted in Clinical Accelerator | Leave a comment

Replicor announces publication of its REP 301 study in HBV / HDV co-infection in The Lancet Gastroenterology & Hepatology

Below, we are re-publishing with permission the press-release issued by Replicor on the 28th of September 2017 MONTREAL, September 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading

Posted in Clinical Accelerator | Leave a comment

Referring physicians: the overlooked resource for faster patient enrolment

It is widely known and understood that the no. 1 cause of delays in clinical trials is inefficient patient enrolment. The problem has become widespread and does not show any signs of abating. According to a TUFTS analysis, 48% of … Continue reading

Posted in ClinAccel.Net, Clinical Accelerator, Cost of Clinical Trials, Patient Enrolment | Leave a comment

Clinical Accelerator forms ClinAccel.Net

Clinical Accelerator forms ClinAccel.Net, a dedicated division focusing on expanding a network of partnering clinical research sites, and fast and efficient patient enrolment into clinical studies Douglas, February 28, 2017 – Clinical Accelerator, a clinical contract research organization with operations … Continue reading

Posted in Clinical Accelerator, Feasibility Assessment, Patient Enrolment | Leave a comment

Regulatory Approval Received for VAL401 in Phase IIB Clinical Trial in Georgia

Below, we are re-publishing with permission the press-release issued by ValiRx on August 11, 2016 London, UK., 11 August 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for … Continue reading

Posted in Clinical Accelerator | Leave a comment

Noxopharm Provides Update on Inaugural Clinical Study

Below, we are re-publishing with permission the press-release issued by Noxopharm on August 10, 2016 Noxopharm has completed putting in place the required logistics to enable it to conduct a clinical study of its lead pipeline drug candidate, NOX66, in Europe, commencing … Continue reading

Posted in Clinical Accelerator | Leave a comment

We are celebrating an important milestone: – our tenth year of operation!

We at Clinical Accelerator are happy to announce the celebration of 10 years successful provision of clinical research services to the biopharma, biotech and medtech industries. Since our inception back in 2006 as a small provider of clinical trial management … Continue reading

Posted in Clinical Accelerator | Leave a comment

Galmed Collaboration Announcement

Clinical Accelerator are very pleased to announce collaboration with Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), on conducting a phase IIB clinical trial for the treatment of patients with overweight or obesity and who are pre diabetic or type II diabetic with … Continue reading

Posted in Clinical Accelerator | Tagged | Leave a comment

Replicor to present pre-clinical and updated clinical data on REP 2139-Ca based combination therapy in chronic HBV and HBV / HDV co-infection at APASL 2016

Below, we are re-publishing with permission the press-release issued by Replicor on the 16th of February 2016 NEW YORK, February 16, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and … Continue reading

Posted in Clinical Accelerator | Leave a comment

Replicor discloses continued improvement of the antiviral response in patients with HBV / HDV co-infection receiving REP 2139-Ca based combination therapy

Below, we are re-publishing with permission the press-release issued by Replicor on the 16th of November 2015 NEW YORK, November 16, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and … Continue reading

Posted in Clinical Accelerator | Leave a comment